Par Pharmaceutical Companies (PRX) Inactive 10-Q2007 Q2 Quarterly report

Filed: 21 Nov 07, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: AAA, Adoxa, affirmed, al, alfuzosin, America, AmerisourceBergen, angina, antagonist, antifungal, arrangement, assigned, Astra, Atlantic, auction, automatic, Aveva, AZ, bad, bicarbonate, BioAlliance, bioequivalence, Biovail, Bureau, cabergoline, cancer, candidate, Cardinal, Carolina, category, cease, cefdinir, cefprozil, Celgene, CEO, cephalosporin, CFO, chemotherapy, Chesler, clearance, Clostridum, committed, commonly, concentrate, condensed, confidential, consent, contacted, coupled, customary, damaged, Debiopharm, Delivery, denial, dexmethylphenidate, diarrhea, Diastat, diazepam, difficle, Difimicin, dispensed, Dispersion, disqualify, distinct, dollar, doxycycline, DRD, driven, Dutch, Earnout, EITF, Elan, eliminated, Emerging, enable, enforceability, enhanced, ER, essentially, examination, examining, Exit, experienced, expert, expertise, exposed, face, FAS, fee, field, FIN, fluctuate, found, framework, FTC, glycol, granularity, group, Hana, hearing, hereto, herewith, hf, highlighting, HIV, human, Idaho, Immtech, immunocompromised, impracticable, improvement, infection, ingredient, inhaler, input, intervening, Iowa, IPC, IPO, IRS, Judge, jurisdiction, lag, Lauriad, LLC, local, Loramyc, lovastatin, low, Lubatkin, maleate, mandated, McKesson, McNeil, Medicare, merger, metoprolol, mg, miconazole, milestone, misrepresentation, Missouri, misuse, mix, ml, MN, monohydrate, mutually, NanoCrystal, Napp, nausea, newly, NitroMistTM, noncurrent, nonrefundable, Nortec, North, NovaDel, objected, objection, ODT, oncology, ondansetron, opportunistic, opted, Orange, Orchid, organization, original, oropharyngeal, Ortho, outflow, outlined, Overview, oxaliplatin, pafuramidine, pediatric, percent, permission, Perrigo, pharmacokinetic, plain, plant, plead, pneumonia, polyethylene, post, predetermined, premium, pretrial, principle, proceed, profile, progressed, Propafenone, propranolol, PTO, Purdue, purpose, qualitative, quoted, radiation, range, ranitidine, reclassification, recognition, reconfirm, recoverable, recovery, rectal, reformulation, reinstated, release, Reliant, relieved, rendered, reset, restructure, restructuring, resubmit, reversal, revisit, ribavirin, royalty, simplified, single, size, Solvay, sooner, sought, South, SR, SRL, stake, strength, summer, surgery, surrendered, suspended, SVC, syrup, Task, Technology, tempered, test, testimony, therapy, therewith, thousand, threshold, tied, title, training, transition, treat, twelve, unaffected, University, unrecognized, USC, Utah, Valeant, validity, vanilla, variability, variable, vary, Veronica, view, vomiting, Walgreen, warrant, warranty, withholding, workforce, Xcel, yield, Zeneca, ZensanaTM, Zofran

Removed: antibiotic, arbitration, argument, assessing, compound, decline, entirety, failed, Germantown, Maryland, microbiological, opposing, reissue, shipping, waived

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

PRX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Par Pharmaceutical Companies, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2007 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Veronica A. Lubatkin, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or Securities Exchange Act of 1934 (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.


/s/ Veronica A. Lubatkin
Veronica A. Lubatkin Executive Vice President and Chief Financial Officer November 21, 2007